Literature DB >> 27241341

A systematic review of pharmacists performing obstructive sleep apnea screening services.

Michael J Cawley1, William J Warning2.   

Abstract

Background Obstructive sleep apnea (OSA) is a chronic sleep disorder associated with a varying degree of upper airway collapse during sleep. Left untreated, OSA can lead to the development of cardiovascular disease including risk of stroke and increased mortality. Pharmacists are the most accessible and underutilized healthcare resource in the community and can have a significant role in screening patients for OSA. The result may include an expedited referral to the patient's general practitioners or sleep disorder specialists for further diagnostic assessment and therapeutic intervention. Aim of the review The primary aim of this review was to identify the current published evidence of pharmacists providing OSA screening services in a community pharmacy setting. Methods A literature search was conducted to identify evidence of pharmacists providing OSA screening services. The literature search including five databases [PubMed, (1946-January 2015), Cumulative Index of Nursing and Allied Health Literature, International Pharmaceutical Abstracts (1970 to January 2015), Cochrane Database of Systematic Reviews and Google Scholar] with search terms of ("pharmacist or pharmacy") AND ("obstructive sleep apnea") AND ("sleep disorders") AND ("continuous positive airway pressure-CPAP") were used. Articles were limited to English and reported in humans. Results A total of seven publications (four Australia, two Switzerland and one France) were selected and evaluated. Pharmacists utilized validated screening tools in 6/7 (86 %) of clinical studies to assist in the identification of patients with sleep disorders in community pharmacies. A total of 1701 pharmacies encompassing 9177 patients were screened in the clinical studies. Pharmacists were able to identify between 21.4 and 67 % of patients that were at risk for developing OSA or required a referral to a general practitioner or sleep disorder specialist for further diagnostic testing. Conclusion Studies assessing the role of pharmacists performing OSA screening services remains limited due to the small number of studies available and differences in methodological assessment. More qualitative studies including randomized controlled trials are needed to better identify the value of pharmacists providing this novel service.

Entities:  

Keywords:  Airway pressure; Obstructive sleep apnea; Pharmacist; Review; Screening services; Sleep disorders

Mesh:

Year:  2016        PMID: 27241341     DOI: 10.1007/s11096-016-0319-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  39 in total

1.  Sleep health awareness in pharmacy undergraduates and practising community pharmacists.

Authors:  K Tze-Min Ang; B Saini; K Wong
Journal:  J Clin Pharm Ther       Date:  2008-12       Impact factor: 2.512

2.  Diagnosis and treatment of sleep apnea-hypopnea syndrome. Spanish Society of Pulmonology and Thoracic Surgery.

Authors:  Patricia Lloberes; Joaquín Durán-Cantolla; Miguel Ángel Martínez-García; José María Marín; Antoni Ferrer; Jaime Corral; Juan Fernando Masa; Olga Parra; Mari Luz Alonso-Álvarez; Joaquín Terán-Santos
Journal:  Arch Bronconeumol       Date:  2011-03       Impact factor: 4.872

Review 3.  Paying pharmacists for patient care: A systematic review of remunerated pharmacy clinical care services.

Authors:  Sherilyn K D Houle; Kelly A Grindrod; Trish Chatterley; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2014-07

4.  The utility of single-channel nasal airflow pressure transducer in the diagnosis of OSA at home.

Authors:  Lydia Makarie Rofail; Keith K H Wong; Gunnar Unger; Guy B Marks; Ronald R Grunstein
Journal:  Sleep       Date:  2010-08       Impact factor: 5.849

5.  Diagnostic pathways for obstructive sleep apnoea in the Australian community: observations from pharmacy-based CPAP providers.

Authors:  Carissa A Hanes; Keith K H Wong; Bandana Saini
Journal:  Sleep Breath       Date:  2015-03-24       Impact factor: 2.816

6.  Treatment experience of people with obstructive sleep apnoea seeking continuous positive airways pressure device provision through community pharmacies: a role for pharmacists?

Authors:  Grace Shoukry; Keith Wong; Delwyn Bartlett; Bandana Saini
Journal:  Int J Pharm Pract       Date:  2011-04-15

7.  An overview of service quality of continuous positive airway pressure services in Australian pharmacies.

Authors:  Carissa A Hanes; Keith K H Wong; Bandana Saini
Journal:  Respirology       Date:  2014-01       Impact factor: 6.424

8.  Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients.

Authors:  Frances Chung; Balaji Yegneswaran; Pu Liao; Sharon A Chung; Santhira Vairavanathan; Sazzadul Islam; Ali Khajehdehi; Colin M Shapiro
Journal:  Anesthesiology       Date:  2008-05       Impact factor: 7.892

9.  Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine.

Authors:  Nancy A Collop; W McDowell Anderson; Brian Boehlecke; David Claman; Rochelle Goldberg; Daniel J Gottlieb; David Hudgel; Michael Sateia; Richard Schwab
Journal:  J Clin Sleep Med       Date:  2007-12-15       Impact factor: 4.062

10.  Screening for sleep disorders in community pharmacies--evaluation of a campaign in Switzerland.

Authors:  K E Hersberger; V P Renggli; A C Nirkko; J Mathis; K Schwegler; K E Bloch
Journal:  J Clin Pharm Ther       Date:  2006-02       Impact factor: 2.512

View more
  1 in total

1.  Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment.

Authors:  Andrea N Natsky; Andrew Vakulin; Ching Li Chai-Coetzer; R Doug McEvoy; Robert J Adams; Billingsley Kaambwa
Journal:  Appl Health Econ Health Policy       Date:  2022-02-10       Impact factor: 3.686

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.